Laurent Bellon
University of Montpellier
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laurent Bellon.
The Journal of Clinical Pharmacology | 2000
Jennifer A. Sandberg; Vann P. Parker; Karin S. Blanchard; David Sweedler; James A. Powell; Arlee Kachensky; Laurent Bellon; Nassim Usman; Thomas Rossing; Ernest C. Borden; Lawrence M. Blatt
The pharmacokinetics and tolerability of a chemically stabilized synthetic ribozyme (ANGIOZYME™) targeting the Flt‐1 VEGF receptor mRNA were evaluated in healthy volunteers. In a placebo‐controlled, single‐dose escalation study, ribozyme was administered as a 4‐hour IV infusion of 10 or 30 mg/m2 or as a SC bolus of 20 mg/m2. Peak ribozyme plasma concentrations of 1.5 and 3.8 μg/mL were observed after the 10 and 30 mg/m2 IV infusions, respectively. When normalized to dose, AUC values as well as peak concentrations increased proportionally as the dose was increased from 10 to 30 mg/m2. Peak concentrations of 0.9 μg/mL were observed approximately 3.25 hours after a 20 mg/m2 SC bolus of ribozyme. The dose‐normalized AUCs obtained after SC dosing were compared to the mean dose‐normalized AUC after IV dosing to estimate an absolute SC bioavailability (f) of approximately 69%. An average elimination half‐life of 28 to 40 minutes was observed after IV administration, which increased to 209 minutes after SC administration. Only 4 of 12 reported adverse events were possibly related to administration of ribozyme (headache and somnolence). Thus, ribozyme administration was well tolerated after a single 4‐hour IV infusion of up to 30 mg/m2 or a single SC bolus of 20 mg/m2.
Nucleosides, Nucleotides & Nucleic Acids | 1992
Laurent Bellon; J. L. Barascut; Jean-Louis Imbach
Abstract A synthetic pathway to reach easily the 4-thio-D-ribofuranose is described. Some corresponding pyrimidine α and β 4′-thioribonucleosides have been synthesized and evaluated as antiviral agents against various viruses.
Nucleosides, Nucleotides & Nucleic Acids | 1997
Laurent Bellon; Christopher T. Workman; Carolyn Gonzalez; Francine E. Wincott
Abstract A convergent approach, based on the reductive amination of 3′-phospho-glycaldehyde-ribozyme 3 with 5′-aminohexyLribozyme 1 generated an amino-linked ribozyme 4 in good yields. Catalytic activity of the cross-linked ribozyme is discussed.
Nucleosides, Nucleotides & Nucleic Acids | 1995
C. Leydier; Laurent Bellon; J. L. Barascut; Jean-Louis Imbach
Abstract The syntheses and the study of nuclease resistance and hydrogen bonding of modified oligoribonucleotides, i.e. 4′-thio-β-D-oligoribonucleotides (4′-S-RNA), are reported.
Nucleosides, Nucleotides & Nucleic Acids | 1993
Laurent Bellon; C. Leydier; J. L. Barascut; Jean-Louis Imbach
Abstract We demonstrate that the procedure of Huang and Hui(4), applied to the D-ribose and involving Ph3P/I2/Imidazole reagent system do not lead to the desired 4-thio-D-ribofuranoside derivative but gives its diastereoisomer 4-thio-L-lyxofuranoside derivative 4
Archive | 1999
James Thompson; Leonid Beigelman; James Mcswiggen; Alexander Karpeisky; Laurent Bellon; Mark Reynolds; Michael Zwick; Thale Jarvis; Tod M. Woolf; Peter Haeberli; Jasenka Matulic-Adamic
Hepatology | 2000
Dennis Macejak; Kristi Jensen; Sharon Jamison; Kristal Domenico; Elisabeth Roberts; Nilabh Chaudhary; Ira von Carlowitz; Laurent Bellon; Myron J. Tong; Andrew Conrad; Pamela Pavco; Lawrence M. Blatt
Archive | 1999
Laurent Bellon; Christopher T. Workman
Hepatology | 2000
Patrice Lee; M P H Lawrence Blatt Dr.; Karin Blanchard; Karyn S. Bouhana; Pamela Pavco; Laurent Bellon; Jennifer A. Sandberg
Journal of the American Chemical Society | 1996
François Morvan; Yogesh S. Sanghvi; Michel Perbost; Jean-Jacques Vasseur; Laurent Bellon